The phase-1 data for R7128 were very promising, and the thinned out competition among HCV polymerase inhibitors made the data even more remarkable. The data for IDIX’s IDX184 are also impressive, although it has so far only been tested in animals and the replicon.
Market Data 
Markets 
AI
